DK1268472T3 - 3-aminopyrazolinhibitorer af cyclinafhængige kinaser - Google Patents

3-aminopyrazolinhibitorer af cyclinafhængige kinaser

Info

Publication number
DK1268472T3
DK1268472T3 DK01948983T DK01948983T DK1268472T3 DK 1268472 T3 DK1268472 T3 DK 1268472T3 DK 01948983 T DK01948983 T DK 01948983T DK 01948983 T DK01948983 T DK 01948983T DK 1268472 T3 DK1268472 T3 DK 1268472T3
Authority
DK
Denmark
Prior art keywords
inhibitors
aminopyrazoline
cyclin
dependent kinases
useful
Prior art date
Application number
DK01948983T
Other languages
English (en)
Inventor
Mark E Salvati
Spencer David Kimball
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1268472T3 publication Critical patent/DK1268472T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01948983T 2000-02-07 2001-01-23 3-aminopyrazolinhibitorer af cyclinafhængige kinaser DK1268472T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18060900P 2000-02-07 2000-02-07
PCT/US2001/002208 WO2001057034A1 (en) 2000-02-07 2001-01-23 3-aminopyrazole inhibitors of cyclin dependent kinases

Publications (1)

Publication Number Publication Date
DK1268472T3 true DK1268472T3 (da) 2004-12-06

Family

ID=22661092

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01948983T DK1268472T3 (da) 2000-02-07 2001-01-23 3-aminopyrazolinhibitorer af cyclinafhængige kinaser

Country Status (11)

Country Link
US (2) US6482842B2 (da)
EP (1) EP1268472B1 (da)
JP (1) JP2003522174A (da)
AT (1) ATE279410T1 (da)
AU (2) AU2001229727B2 (da)
CA (1) CA2399274A1 (da)
DE (1) DE60106409T2 (da)
DK (1) DK1268472T3 (da)
ES (1) ES2228905T3 (da)
PT (1) PT1268472E (da)
WO (1) WO2001057034A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2223922T1 (sl) 2000-04-25 2016-04-29 Icos Corporation Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2004044226A2 (en) * 2002-11-12 2004-05-27 The Board Of Trustees Of The University Of Illinois Induction of cellular senescence by cdk4 disruption for tumor supression and regression
JP2006526015A (ja) * 2003-05-02 2006-11-16 エラン ファーマシューティカルズ,インコーポレイテッド 炎症疾患治療のためのブラジキニンb1受容体アンタゴニストとしての4−ブロモ−5−(2−クロロ−ベンゾイルアミノ)−1h−ピラゾール−3−カルボン酸アミド誘導体および関連化合物
WO2005016888A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
US20070275918A1 (en) * 2003-11-07 2007-11-29 The Board Of Trustees Of The University Of Illinois Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
EP1899304A1 (en) * 2005-05-23 2008-03-19 Arena Pharmaceuticals, Inc. 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof
CA3092449A1 (en) 2008-11-13 2010-05-20 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
PE20141792A1 (es) 2012-03-05 2014-12-07 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
CA2934531C (en) 2013-12-20 2020-02-25 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416683A (en) * 1980-09-16 1983-11-22 Eli Lilly And Company Benzamides, compositions and agricultural method
JPS6033552A (ja) * 1983-08-04 1985-02-20 Fuji Photo Film Co Ltd カラ−画像形成方法
DE3575130D1 (de) * 1984-05-12 1990-02-08 Fisons Plc Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung.
JPH0743522B2 (ja) * 1985-07-05 1995-05-15 コニカ株式会社 5―アミノ―1h―ピラゾール系化合物を用いる写真用マゼンタカプラーの合成方法
JPH01258695A (ja) * 1988-04-07 1989-10-16 Yamanouchi Pharmaceut Co Ltd (ピラゾリルアミノ)メチレンビス(ホスホン酸)誘導体及びその医薬
WO1993005044A1 (en) * 1991-09-03 1993-03-18 Yamanouchi Pharmaceutical Co.,Ltd. Pyrazolotriazole derivative
JPH06210063A (ja) * 1993-01-14 1994-08-02 Kousaku Ishikawa パチンコゲーム機における持ち玉返却機構
ES2219670T3 (es) * 1994-11-10 2004-12-01 Millennium Pharmaceuticals, Inc. Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis.
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
DE19744676A1 (de) 1997-10-10 1999-04-15 Forschungszentrum Borstel Zent Kombinationspräparate für die Therapie von Tumoren
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6958333B1 (en) 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
ES2249270T3 (es) 1999-08-12 2006-04-01 Pharmacia Italia S.P.A. Derivados de 3(5)-aminopirazol, procedimiento para su preparacion y su uso como agentes antitumorales.

Also Published As

Publication number Publication date
AU2001229727B2 (en) 2004-10-14
JP2003522174A (ja) 2003-07-22
CA2399274A1 (en) 2001-08-09
DE60106409D1 (de) 2004-11-18
US20010047019A1 (en) 2001-11-29
EP1268472A1 (en) 2003-01-02
EP1268472B1 (en) 2004-10-13
WO2001057034A1 (en) 2001-08-09
US6610724B2 (en) 2003-08-26
ES2228905T3 (es) 2005-04-16
AU2972701A (en) 2001-08-14
US6482842B2 (en) 2002-11-19
DE60106409T2 (de) 2006-02-02
PT1268472E (pt) 2005-01-31
ATE279410T1 (de) 2004-10-15
US20030018058A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
DK1240165T3 (da) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamid-inhibitorer af cyclinafhængige kinaser
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
EE05481B1 (et) Kinasoliini derivaadid kasvajate raviks
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
DK1268472T3 (da) 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
MXPA02005844A (es) Inhibidores de cinasas de proteina.
TW200607505A (en) Fused heterocyclic kinase inhibitors
NO2010002I2 (no) Toceranibfosfat.
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
MY125768A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren
ATE389655T1 (de) Pyrimidinderivate
ECSP003821A (es) Inhibidores de n-(5(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina
ECSP003826A (es) Inhibidores de n-(5(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina
UY26732A1 (es) N-(5-(5-alquil-2-oxazolil)metil)tio)-2- tiazolil) carboxamidas inhibidoras de cinasa dependientes de la ciclina